Novartis Korea to offer cash compensation program for leukemia patients in Korea

Published: 2003-02-26 06:57:00

Updated: 2003-02-26 06:57:00

The Korea Orphan Drug Center said that those patients taking Glivec from this February will benefit from Novartis Korea's compensation program to cover patient's out-of-pocket of Glivec's treatment costs by ten percent in cash, provided that those who have received Glivec capsule 100mg and citize...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK